StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
38
Publishing Date
2023 - 10 - 09
1
2023 - 09 - 13
2
2023 - 08 - 25
1
2023 - 08 - 03
1
2023 - 07 - 24
1
2023 - 06 - 30
1
2023 - 02 - 21
2
2022 - 12 - 21
1
2022 - 12 - 08
1
2022 - 09 - 22
1
2022 - 09 - 20
1
2022 - 08 - 29
1
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 03 - 23
1
2022 - 03 - 01
1
2022 - 01 - 11
1
2021 - 12 - 22
1
2021 - 12 - 20
1
2021 - 12 - 14
1
2021 - 10 - 18
1
2021 - 09 - 28
2
2021 - 09 - 13
1
2021 - 08 - 19
1
2021 - 08 - 05
1
2021 - 08 - 04
1
2021 - 07 - 29
1
2021 - 07 - 21
1
2021 - 07 - 16
1
2021 - 06 - 30
1
2021 - 06 - 24
1
2021 - 06 - 22
1
2021 - 06 - 16
1
2021 - 04 - 21
1
2020 - 12 - 03
1
Sector
Health technology
38
Tags
Agreement
1
Alcohol use disorder
2
Alliances
1
Alzheimer
1
Alzheimer's
1
Alzheimer's disease
1
Alzheimer’s
1
Amvuttra
1
Application
10
Approval
2
Authorized
1
Biocanada
2
Biotech
1
Brii-835
1
Cardiovascular
1
Children
1
Clearance
1
Clinical-trials-phase-i
3
Clinical-trials-phase-ii
1
Clinical-trials-phase-iii
1
Diabetes
1
Disease
4
Drug
9
Enroll
1
Europe
3
Expansion
1
Fda
7
Fda clearance
1
Fda-approvals
1
Food
5
Genetown
9
Hepatitis
4
Hypertension
2
Infection
1
Iot
1
License
1
Liver
2
Liver disease
2
Lone-star-bio
1
Market
1
Media
2
Meeting
2
N/a
9
Nephropathy
2
New drug
3
Onpattro
3
Oxlumo
2
Partnership
1
Pharmaceutical
1
Phase 1
2
Phase 2
6
Phase 3
2
Positive
5
Research
8
Results
2
Review
2
Technology
2
Topline
2
Treatment
38
Trial
7
Entities
3m company
21
Abbott laboratories
62
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
51
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
211
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
66
Moleculin biotech, inc.
28
Novartis ag
144
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
23
Pfizer, inc.
75
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
297
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
54
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
AGIO
1
ALNY
38
EDIT
1
GLAXF
1
GSK
1
IONS
1
JNJ
1
LLY
6
NVO
6
NVS
2
NVSEF
2
REGN
2
SGMO
1
SNY
17
SNYNF
17
TEVJF
1
TMO
1
VBIV
1
VIR
2
Exchanges
Nasdaq
38
Nyse
8
Crawled Date
2023 - 10 - 09
1
2023 - 09 - 13
2
2023 - 08 - 25
1
2023 - 08 - 03
1
2023 - 07 - 24
1
2023 - 06 - 30
1
2023 - 02 - 21
2
2022 - 12 - 21
1
2022 - 12 - 08
1
2022 - 09 - 22
1
2022 - 09 - 20
1
2022 - 08 - 29
1
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 03 - 23
1
2022 - 03 - 01
1
2022 - 01 - 11
1
2021 - 12 - 22
1
2021 - 12 - 20
1
2021 - 12 - 14
1
2021 - 10 - 18
1
2021 - 09 - 28
2
2021 - 09 - 13
1
2021 - 08 - 19
1
2021 - 08 - 05
1
2021 - 08 - 04
1
2021 - 07 - 29
1
2021 - 07 - 21
1
2021 - 07 - 16
1
2021 - 06 - 30
1
2021 - 06 - 24
1
2021 - 06 - 22
1
2021 - 06 - 16
1
2021 - 04 - 21
1
2020 - 12 - 03
1
Crawled Time
03:00
1
06:00
1
07:00
1
11:00
1
12:00
6
12:15
3
12:30
2
13:00
3
13:20
2
13:30
1
14:00
4
14:30
1
15:00
4
16:00
2
18:00
2
21:00
2
22:00
2
Source
www.alnylam.com
4
www.biospace.com
29
www.globenewswire.com
2
www.prnewswire.com
2
www.vbivaccines.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Alnylam pharmaceuticals, inc.
save search
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-10-09
(Crawled : 14:30)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-14.1%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-17.6%
|
O:
-4.06%
H:
2.17%
C:
-0.83%
fda
drug
treatment
application
response
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-09-13
(Crawled : 22:00)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-15.3%
|
O:
-1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-15.51%
|
O:
-0.99%
H:
0.0%
C:
0.0%
fda
positive
treatment
meeting
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-09-13
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-15.3%
|
O:
-1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-15.51%
|
O:
-0.99%
H:
0.0%
C:
0.0%
fda
drug
review
treatment
application
Advancements in Diagnosis and Treatment Fuel Rising Prevalence of Thalassemia, Driving Market to 2028
Published:
2023-08-25
(Crawled : 03:00)
- prnewswire.com
GLAXF
|
News
|
$20.305
630
|
Health Technology
|
18.89%
|
O:
2.25%
H:
0.0%
C:
0.0%
NVS
|
News
|
$97.31
2.3%
2.3M
|
Health Technology
|
-6.02%
|
O:
0.67%
H:
0.37%
C:
0.26%
GSK
|
News
|
$41.13
1.33%
1.1M
|
Health Technology
|
17.75%
|
O:
0.67%
H:
0.45%
C:
0.2%
SGMO
|
News
|
$0.535
4.88%
1.8M
|
Health Technology
|
-43.96%
|
O:
-3.19%
H:
0.0%
C:
0.0%
IONS
|
$42.2
2.75%
190K
|
Health Technology
|
3.17%
|
O:
0.0%
H:
1.68%
C:
1.28%
EDIT
|
News
|
$5.66
1.07%
750K
|
Health Technology
|
-36.44%
|
O:
0.11%
H:
1.25%
C:
-0.57%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-21.94%
|
O:
-0.12%
H:
2.12%
C:
1.45%
treatment
market
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Published:
2023-08-03
(Crawled : 11:00)
- globenewswire.com
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-21.03%
|
O:
-1.35%
H:
5.58%
C:
4.38%
AGIO
|
$31.645
4.75%
350K
|
Health Technology
|
16.87%
|
O:
-2.4%
H:
5.98%
C:
2.81%
license
treatment
potential
agreement
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Published:
2023-07-24
(Crawled : 06:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-15.56%
|
O:
-0.88%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-27.86%
|
O:
0.06%
H:
0.0%
C:
0.0%
partnership
treatment
risk
hypertension
roche
cardiovascular
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-06-30
(Crawled : 14:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-12.63%
|
O:
0.94%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-23.69%
|
O:
1.45%
H:
1.03%
C:
-2.01%
onpattro
fda
treatment
meeting
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Published:
2023-02-21
(Crawled : 15:00)
- globenewswire.com
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-2.28%
|
O:
0.79%
H:
0.0%
C:
0.0%
REGN
|
News
|
$908.42
0.92%
130K
|
Health Technology
|
20.22%
|
O:
-0.09%
H:
0.59%
C:
-0.21%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-34.56%
|
O:
-2.68%
H:
0.6%
C:
-7.83%
treatment
fda
disease
children
review
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-02-21
(Crawled : 14:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-2.28%
|
O:
0.79%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-34.56%
|
O:
-2.68%
H:
0.6%
C:
-7.83%
onpattro
treatment
drug
application
food
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Published:
2022-12-21
(Crawled : 13:20)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
1.42%
|
O:
6.05%
H:
2.65%
C:
0.66%
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-1.63%
|
O:
2.63%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-38.63%
|
O:
-0.05%
H:
2.34%
C:
1.64%
treatment
application
diabetes
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2022-12-08
(Crawled : 22:00)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-1.83%
|
O:
0.5%
H:
0.16%
C:
0.16%
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-2.49%
|
O:
-1.32%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-36.98%
|
O:
0.43%
H:
3.16%
C:
2.44%
onpattro
treatment
drug
application
food
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published:
2022-09-22
(Crawled : 13:20)
- biospace.com/
VIR
|
$8.235
1.67%
240K
|
Health Technology
|
-56.68%
|
O:
-1.55%
H:
2.68%
C:
1.2%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-29.36%
|
O:
-0.53%
H:
0.0%
C:
-1.26%
vir-2218
treatment
hepatitis
vir-3434
virus
trial
infection
phase 2
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Published:
2022-09-20
(Crawled : 12:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
14.76%
|
O:
-1.18%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-32.5%
|
O:
0.0%
H:
1.68%
C:
-1.85%
amvuttra
treatment
europe
approval
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published:
2022-08-29
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
11.48%
|
O:
-1.08%
H:
0.0%
C:
0.0%
REGN
|
News
|
$908.42
0.92%
130K
|
Health Technology
|
50.99%
|
O:
-0.64%
H:
1.24%
C:
0.07%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-30.89%
|
O:
-0.56%
H:
1.41%
C:
-0.34%
treatment
nephropathy
positive
study
phase 2
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Published:
2022-06-14
(Crawled : 07:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-7.73%
|
O:
-1.73%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
14.12%
|
O:
0.77%
H:
6.48%
C:
3.71%
treatment
fda
approval
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published:
2022-06-09
(Crawled : 12:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-12.95%
|
O:
-0.88%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
7.02%
|
O:
1.59%
H:
0.68%
C:
-2.46%
treatment
nephropathy
topline
positive
phase 2
The Worldwide Paroxysmal Nocturnal Hemoglobinuria Treatment Industry is Expected to Reach $4.7 Billion by 2027
Published:
2022-03-23
(Crawled : 13:30)
- prnewswire.com
TMO
|
News
|
$575.155
4.88%
1.4M
|
Health Technology
|
-7.21%
|
O:
-1.66%
H:
0.0%
C:
0.0%
NVS
|
News
|
$97.31
2.3%
2.3M
|
Health Technology
|
10.37%
|
O:
-0.6%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$150.09
0.65%
3.9M
|
Health Technology
|
-15.27%
|
O:
-0.38%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-11.01%
|
O:
-0.59%
H:
1.0%
C:
-0.32%
treatment
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published:
2022-03-01
(Crawled : 16:00)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-15.3%
|
O:
-3.33%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-11.17%
|
O:
-1.3%
H:
0.0%
C:
0.0%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-7.64%
|
O:
0.65%
H:
3.47%
C:
2.28%
oxlumo
new drug
treatment
application
drug
food
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
Published:
2022-01-11
(Crawled : 15:00)
- biospace.com/
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-2.91%
|
O:
-0.31%
H:
0.0%
C:
0.0%
treatment
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2021-12-22
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$47.85
1.49%
920K
|
Health Technology
|
-6.63%
|
O:
-0.59%
H:
1.12%
C:
0.93%
ALNY
|
$146.64
0.58%
200K
|
Health Technology
|
-26.96%
|
O:
-5.24%
H:
2.44%
C:
-0.93%
alzheimer
treatment
application
disease
alzheimer’s
alzheimer's disease
alzheimer's
← Previous
1
2
Next →
Gainers vs Losers
87%
13%
Top 10 Gainers
MTTR
|
News
M
|
$4.64
166.67%
18M
|
AGBA
|
$2.61
108.8%
41M
|
Finance
CZOO
|
$9.32
86.77%
18M
|
EDBL
|
News
|
$6.7
78.19%
1.7M
|
OPRT
|
News
|
$3.37
49.78%
8.9M
|
Finance
MTC
|
$2.14
37.18%
4.9M
|
Technology Services
VNRX
|
$0.7945
32.42%
3.1M
|
Health Technology
MLEC
|
$1.79
27.86%
2.6M
|
n/a
PALI
|
$6.29
27.59%
22M
|
Manufacturing
MCRB
|
$0.7902
26.51%
6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.